Every Tenth New European Drug Was Developed in Turku
Three different drugs developed in Finland have received a marketing authorization during the past year, and a positive decision is expected on the application of a fourth marketing authorization.
The FDA has granted a marketing authorization for two drugs developed in Turku, Finland--the IUD Skyla, developed, by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. With the marketing authorization of Selincro, a Biotie drug intended for the treatment of alcohol addiction, granted by the EMA, that brings the total number of drugs developed in Turku and granted marketing authorizations to three, with a fourth expected to follow.
There are only about 30 new drugs that receive the marketing authorization in Europe per year, a number that makes the turnout from Turku even more significant.
Read the full release here.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
